Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Video

Updated: Jul 11, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

Optimization of a screening lead for factor VIIa/TF.

W B Young¹, A Kolesnikov, R Rai

¹Department of Medicinal Chemistry, Axys Pharmaceuticals, Inc., 385 Oyster Point Blvd., South San Francisco, CA 94080, USA. wendy_young@axyspharm.com

Bioorganic & Medicinal Chemistry Letters

|August 31, 2001

Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

PROTECTION OF CONFIDENTIAL MEDICAL INFORMATION IN UKRAINE: PROBLEMS OF LEGAL REGULATION.

Georgian medical news·2024

Same author

A dataset of soil microstructure features and the weather conditions affecting them from 2005 to 2021 in the Caspian Depression.

Data in brief·2022

Same author

The lower pT limit of deep hydrocarbon synthesis by CaCO<sub>3</sub> aqueous reduction.

Scientific reports·2017

Same author

Post-mortem analysis of islet pathology in type 1 diabetes illuminates the life and death of the beta cell.

Clinical and experimental immunology·2009

Same author

Suboptimal control of blood pressure at hospital discharge in stroke patients.

Irish journal of medical science·2009

Same author

A freeze-dried formulation of bacteriophage encapsulated in biodegradable microspheres.

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V·2009

Structure-based design yielded a potent 3nM factor VIIa/TF inhibitor. This new inhibitor demonstrates enhanced selectivity against related enzymes, marking a significant advancement in drug development.

Area of Science:

Biochemistry
Medicinal Chemistry
Drug Discovery

Background:

Factor VIIa (FVIIa) and tissue factor (TF) are critical in the coagulation cascade.
Inhibitors of FVIIa/TF are sought for therapeutic intervention in thrombotic disorders.
Optimizing inhibitor selectivity is crucial to minimize off-target effects.

Purpose of the Study:

To describe the structure-based design and optimization of a novel FVIIa/TF inhibitor.
To achieve high potency and improved selectivity for the target enzyme complex.

Main Methods:

Structure-based drug design utilizing X-ray crystallography.
Iterative lead optimization through medicinal chemistry.
Biochemical assays to determine enzyme inhibition constants (Ki) and selectivity profiles.

More Related Videos

Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay (EMSA) and DNA-affinity Precipitation Assay (DAPA)

Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay (EMSA) and DNA-affinity Precipitation Assay (DAPA)

Published on: August 21, 2016

Extracellular Vesicle Tissue Factor Activity Assay

Extracellular Vesicle Tissue Factor Activity Assay

Published on: December 29, 2023

Related Experiment Videos

Last Updated: Jul 11, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay (EMSA) and DNA-affinity Precipitation Assay (DAPA)

Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay (EMSA) and DNA-affinity Precipitation Assay (DAPA)

Published on: August 21, 2016

Extracellular Vesicle Tissue Factor Activity Assay

Extracellular Vesicle Tissue Factor Activity Assay

Published on: December 29, 2023

Main Results:

Identification of a screening lead with initial inhibitory activity.
Progression of the lead compound through structure-based design.
Achieved a final inhibitor with a 3nM potency against FVIIa/TF.
Demonstrated significantly improved selectivity compared to related serine proteases.

Conclusions:

Structure-based design is effective for developing potent and selective enzyme inhibitors.
The novel 3nM FVIIa/TF inhibitor represents a promising candidate for further preclinical development.
Enhanced selectivity profile reduces potential risks associated with off-target enzyme inhibition.